AIMS: Data about long-term clinical outcomes of revascularization procedures, especially for autologous cell therapy (ACT), in diabetic patients with chronic limb-threatening ischaemia (CLTI) are lacking. The aim of our study was to compare the mortality and amputation rates in patients with diabetic foot ulcers (DFU) and CLTI treated by ACT with patients treated by repeated percutaneous transluminal angioplasty (re-PTA) and those treated conservatively. MATERIALS AND METHODS: One-hundred and thirty patients with DFU and CLTI (defined as transcutaneous oxygen pressure-TcPO2 <30 mmHg after unsuccessful standard revascularization) treated in our foot clinic over 9 years were enrolled in the study. Forty-five patients were treated by ACT, 43 patients underwent re-PTA, and 42 patients were treated conservatively and formed the control group. Overall survival, amputation-free survival (AFS) and major amputation rate were assessed over a 7-year follow-up period. RESULTS: Baseline demographic characteristics and comorbidities were similar between groups. However, patients in ACT and control groups had significantly worse baseline angiograms in accordance with Graziani and GLASS (infrapopliteal region) classifications than the re-PTA group (both p < 0.001), but there were no differences in baseline values of TcPO2 between groups. AFS in the ACT and re-PTA groups were significantly longer compared to control (both p < 0.001). The rate of major amputation was significantly lower in both active groups (both p < 0.001). The re-PTA group showed significantly longer overall survival compared to the control group (p < 0.001), but there was no significant difference between ACT and control groups (p = 0.063) and ACT and re-PTA groups (p = 0.081) in this parameter. CONCLUSIONS: Our study showed significantly longer AFS and lower major amputation rates in patients treated by ACT and re-PTA in contrast to patients treated conservatively. Overall survival was significantly longer only in the re-PTA group. ACT was shown to be effective in long-term limb salvage in people with no-option CLTI.

1st Faculty of Medicine Charles University Prague Czech Republic

2nd Faculty of Medicine Charles University Prague Czech Republic

Diabetes Center Institute for Clinical and Experimental Medicine Prague Czech Republic

Diabetes Center Tameside and Glossop Integrated Care NHS Foundation Trust Ashton under Lyne and University of Manchester Manchester UK

See more in PubMed

Cimellaro A, Cavallo M, Mungo M, et al. Cardiovascular effectiveness and safety of antidiabetic drugs in patients with type 2 diabetes and peripheral artery disease: systematic review. Medicina (Kaunas). 2024;60(9):1542. PubMed PMC

Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ. 2006;333(7566):475‐480. PubMed PMC

Luengo‐Fernandez R, Walli‐Attaei M, Gray A, et al. Economic burden of cardiovascular diseases in the European Union: a population‐based cost study. Eur Heart J. 2023;44(45):4752‐4767. PubMed PMC

van Haelst STW, Koopman C, den Ruijter HM, et al. Cardiovascular and all‐cause mortality in patients with intermittent claudication and critical limb ischaemia. Br J Surg. 2018;105(3):252‐261. PubMed

Bradbury AW, Moakes CA, Popplewell M, et al. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra‐popliteal, with or without an additional more proximal infra‐inguinal revascularisation procedure to restore limb perfusion (BASIL‐2): an open‐label, randomised, multicentre, phase 3 trial. Lancet. 2023;401(10390):1798‐1809. PubMed

Farber A, Menard MT, Conte MS, et al. Surgery or endovascular therapy for chronic limb‐threatening ischemia. N Engl J Med. 2022;387(25):2305‐2316. PubMed

Umekawa K, Kurabayashi T, Asato H, Iida T, Suzuki A, Tasaki M. A free bypass flap for chronic limb‐threatening ischemia. Plast Reconstr Surg Glob Open. 2024;12(6):e5875. PubMed PMC

Yanishi K, Shoji K, Fujioka A, Hori Y, Yukawa A, Matoba S. Impact of therapeutic angiogenesis using autologous bone marrow‐derived mononuclear cell implantation in patients with No‐option critical limb ischemia. Ann Vasc Dis. 2020;13(1):13‐22. PubMed PMC

Kwiatkowski T, Zbierska‐Rubinkiewicz K, Krzywoń JW, et al. Cellular therapies in no‐option critical limb ischemia: present status and future directions. Postepy Kardiol Interwencyjnej. 2022;18(4):340‐349. PubMed PMC

Desai S, Sharma D, Srinivas R, et al. Mesenchymal stromal cell therapy (REGENACIP((R))), a promising treatment option in chronic limb threatening ischemia – a narrative review. Stem Cell Res Ther. 2024;15(1):352. PubMed PMC

Jeyaraman M, Nagarajan S, Maffulli N, et al. Stem cell therapy in critical limb ischemia. Cureus. 2023;15(7):e41772. PubMed PMC

Powell RJ, Marston WA, Berceli SA, et al. Cellular therapy with Ixmyelocel‐T to treat critical limb ischemia: the randomized, double‐blind, placebo‐controlled RESTORE‐CLI trial. Mol Ther. 2012;20(6):1280‐1286. PubMed PMC

Sharma S, Pandey NN, Sinha M, et al. Randomized, double‐blind, placebo‐controlled trial to evaluate safety and therapeutic efficacy of angiogenesis induced by intraarterial autologous bone marrow‐derived stem cells in patients with severe peripheral arterial disease. J Vasc Interv Radiol. 2021;32(2):157‐163. PubMed

Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized‐start, placebo‐controlled pilot trial (PROVASA). Circ Cardiovasc Interv. 2011;4(1):26‐37. PubMed

Teraa M, Sprengers RW, Schutgens RE, et al. Effect of repetitive intra‐arterial infusion of bone marrow mononuclear cells in patients with no‐option limb ischemia: the randomized, double‐blind, placebo‐controlled rejuvenating endothelial progenitor cells via transcutaneous intra‐arterial supplementation (JUVENTAS) trial. Circulation. 2015;131(10):851‐860. PubMed

Sojakova D, Husakova J, Fejfarova V, et al. The use of autologous cell therapy in diabetic patients with chronic limb‐threatening ischemia. Int J Mol Sci. 2024;25(18):10184. PubMed PMC

Sun Y, Zhao J, Zhang L, Li Z, Lei S. Effectiveness and safety of stem cell therapy for diabetic foot: a meta‐analysis update. Stem Cell Res Ther. 2022;13(1):416. PubMed PMC

Brownrigg JR, Hinchliffe RJ, Apelqvist J, et al. Performance of prognostic markers in the prediction of wound healing or amputation among patients with foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2016;32(Suppl 1):128‐135. PubMed

Dubsky M, Jirkovska A, Bem R, et al. Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. Diabetes Metab Res Rev. 2013;29(5):369‐376. PubMed

Dubsky M, Jirkovská A, Bem R, et al. Comparison of the effect of stem cell therapy and percutaneous transluminal angioplasty on diabetic foot disease in patients with critical limb ischemia. Cytotherapy. 2014;16(12):1733‐1738. PubMed

Tian HM, Lin FP, Du XJ, Zen XN, Yu XJ. PTA combined with transplantation of autologous bone marrow stem cells for diabetic foot: observation of clinical effect. J Interv Radiol. 2016;25(12):1040‐1043.

Qin HL, Zhu XH, Zhang B, Zhou L, Wang WY. Clinical evaluation of human umbilical cord mesenchymal stem cell transplantation after angioplasty for diabetic foot. Exp Clin Endocrinol Diabetes. 2016;124(8):497‐503. PubMed

Beltran‐Camacho L, Rojas‐Torres M, Duran‐Ruiz MC. Current status of angiogenic cell therapy and related strategies applied in critical limb ischemia. Int J Mol Sci. 2021;22(5):2335. PubMed PMC

Dubsky M, Husáková J, Bem R, et al. Comparison of the impact of autologous cell therapy and conservative standard treatment on tissue oxygen supply and course of the diabetic foot in patients with chronic limb‐threatening ischemia: a randomized controlled trial. Front Endocrinol (Lausanne). 2022;13:888809. PubMed PMC

Scatena A, Petruzzi P, Maioli F, et al. Autologous peripheral blood mononuclear cells for limb salvage in diabetic foot patients with No‐option critical limb ischemia. J Clin Med. 2021;10(10):2213. PubMed PMC

Norgren L, Weiss N, Nikol S, et al. PACE: randomized, controlled, multicentre, multinational, phase III study of PLX‐PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial. Br J Surg. 2024;111(2):znad437. PubMed PMC

Meloni M, Giurato L, Andreadi A, et al. Peripheral blood mononuclear cells: a new frontier in the Management of Patients with diabetes and No‐option critical limb Ischaemia. J Clin Med. 2023;12(19):6123. PubMed PMC

Dubsky M, Husáková J, Sojáková D, Fejfarová V, Jude EB, et al. Cell therapy of severe ischemia in people with diabetic foot ulcers‐do we have enough evidence? Mol Diagn Ther. 2023;27(6):673‐683. PubMed PMC

Moazzami B, Mohammadpour Z, Zabala ZE, et al. Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev. 2022;7(7):CD008347. PubMed PMC

Young MJ, McCardle JE, Randall LE, Barclay JI. Improved survival of diabetic foot ulcer patients 1995‐2008: possible impact of aggressive cardiovascular risk management. Diabetes Care. 2008;31(11):2143‐2147. PubMed PMC